Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 5/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21677293 | 0.85 | KCNN4 (0.47) | KCNN4KCNE1KCNQ1CTNNB1WNT3A | |
| SCHEMBL18683357 | 0.85 | KCNN4 (0.47) | KCNN4KCNE1KCNQ1CTNNB1WNT3A | |
| SCHEMBL17118636 | 0.80 | NLRP3 (0.42) | KCNN4HPGDCYP2C19KMT2ARAB9A | |
| SCHEMBL21677155 | 0.74 | KCNN4 (0.39) | KCNN4KCNE1KCNQ1CTNNB1WNT3A | |
| SCHEMBL18683297 | 0.74 | KCNN4 (0.39) | KCNN4KCNE1KCNQ1CTNNB1WNT3A | |
| SCHEMBL18117413 | 0.72 | KCNN4 (0.47) | KCNN4KCNE1KCNQ1CTNNB1WNT3A | |
| SCHEMBL15909862 | 0.71 | PDK1 (0.35) | KCNN4KCNE1KCNQ1CYP2C19KMT2A | |
| SCHEMBL15903126 | 0.71 | PDK1 (0.35) | KCNN4KCNE1KCNQ1CYP2C19KMT2A | |
| SCHEMBL10197999 | 0.69 | KCNN4 (0.45) | KCNN4KCNE1KCNQ1CTNNB1WNT3A | |
| SCHEMBL15142455 | 0.69 | KCNN4 (0.35) | KCNN4KCNE1KCNQ1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883779-B2 | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them | SHINOGI & CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8883779-B2 | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them | SHINOGI & CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2703399-A1 | OXAZINE DERIVATIVE AND BACE 1 INHIBITOR CONTAINING SAME | Shionogi & Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20140051691-A1 | OXAZINE DERIVATIVES AND A PHARMACEUTICAL COMPOSITION FOR INHIBITING BACE1 CONTAINING THEM | SHIONOGI & CO., LTD. (JP) | 2014-02-20 | — | — | US | disclosed |
| US-20140051691-A1 | OXAZINE DERIVATIVES AND A PHARMACEUTICAL COMPOSITION FOR INHIBITING BACE1 CONTAINING THEM | SHIONOGI & CO., LTD. (JP) | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051691-A1 | OXAZINE DERIVATIVES AND A PHARMACEUTICAL COMPOSITION FOR INHIBITING BACE1 CONTAINING THEM | BACE1, BACE2, APP | KCNN4 3325/4885KCNE1 2324/4885KCNQ1 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.